The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): A new time-bomb in the making?
作者信息
Arif Taha Bin
机构信息
Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
出版信息
Infect Control Hosp Epidemiol. 2022 Mar;43(3):415-416. doi: 10.1017/ice.2020.1434. Epub 2021 Jan 11.
Abstract
摘要
相似文献
1
The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): A new time-bomb in the making?2019冠状病毒病（COVID-19）的501.V2和B.1.1.7变体：正在形成的新定时炸弹？
Infect Control Hosp Epidemiol. 2022 Mar;43(3):415-416. doi: 10.1017/ice.2020.1434. Epub 2021 Jan 11.
2
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.mRNA-1273 对 SARS-CoV-2 变异株的血清中和活性。
J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22.
3
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19（Sars-Cov-2）的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
4
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。
Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.
5
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers.英国和南非严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）变异株在接受 BNT162b2 疫苗接种或新冠肺炎（COVID-19）康复的医护人员中的中和异质性。
Clin Infect Dis. 2022 Mar 1;74(4):707-710. doi: 10.1093/cid/ciab492.
6
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.在新诊断的COVID-19患者的鼻咽样本中，501Y.V2新冠病毒变体的病毒载量介于501Y.V1变体和历史变体之间。
J Infect. 2021 Jul;83(1):119-145. doi: 10.1016/j.jinf.2021.04.023. Epub 2021 Apr 28.
7
Real-Time Genomic Surveillance for SARS-CoV-2 Variants of Concern, Uruguay.实时基因组监测关注的 SARS-CoV-2 变异株，乌拉圭。
Emerg Infect Dis. 2021 Nov;27(11):2957-2960. doi: 10.3201/eid2711.211198. Epub 2021 Aug 26.
8
Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity.针对 SARS-CoV-2 变异株的免疫反应：关注严重程度、易感性和预先存在的免疫。
J Infect Public Health. 2022 Feb;15(2):277-288. doi: 10.1016/j.jiph.2022.01.007. Epub 2022 Jan 13.
9
Evolving biothreat of variant SARS-CoV-2 - molecular properties, virulence and epidemiology.不断演变的 SARS-CoV-2 变体生物威胁——分子特性、毒力和流行病学。
Eur Rev Med Pharmacol Sci. 2021 Jun;25(12):4405-4412. doi: 10.26355/eurrev_202106_26151.
10
A Novel Strategy for the Detection of SARS-CoV-2 Variants Based on Multiplex PCR-Mass Spectrometry Minisequencing Technology.一种基于多重 PCR-质谱微测序技术的 SARS-CoV-2 变体检测新策略。
Microbiol Spectr. 2021 Dec 22;9(3):e0126721. doi: 10.1128/Spectrum.01267-21. Epub 2021 Nov 17.
引用本文的文献
1
The high mutation rate at the D614G hotspot-furin cleavage site region increases the priming efficiency of the Spike protein by furin protease: analysis of Indonesian SARS-CoV-2 G614 variants obtained during the early COVID-19 pandemic.D614G热点-弗林蛋白酶切割位点区域的高突变率提高了弗林蛋白酶对刺突蛋白的启动效率：对新冠疫情早期获得的印度尼西亚SARS-CoV-2 G614变体的分析。
Virusdisease. 2023 May 31;34(2):1-10. doi: 10.1007/s13337-023-00827-w.
2
Binding affinity improvement analysis of multiple-mutant Omicron on 2019-nCov to human ACE2 by in silico predictions.通过计算机预测分析多种突变株奥密克戎对人类 ACE2 的结合亲和力。
J Mol Model. 2023 Apr 24;29(5):155. doi: 10.1007/s00894-023-05536-1.
3
Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.经典与下一代 SARS-CoV-2 疫苗平台：生物技术策略和基因组变异。
Int J Environ Res Public Health. 2022 Feb 18;19(4):2392. doi: 10.3390/ijerph19042392.
4
Changes to the practice of pediatric otolaryngology as a consequence of the COVID-19 pandemic.COVID-19 大流行对小儿耳鼻喉科实践的影响。
Int J Pediatr Otorhinolaryngol. 2022 Feb;153:111021. doi: 10.1016/j.ijporl.2021.111021. Epub 2022 Jan 1.
5
A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.对 SARS-CoV-2（COVID-19）复杂性、新兴变异体以及治疗干预和疫苗接种策略的批判性分析。
Biomed Pharmacother. 2022 Feb;146:112550. doi: 10.1016/j.biopha.2021.112550. Epub 2021 Dec 15.
6
An evaluation of community satisfaction with the government's COVID-19 pandemic response in Aceh, Indonesia.对印度尼西亚亚齐省社区对政府应对新冠疫情措施满意度的评估。
Int J Disaster Risk Reduct. 2022 Feb 1;69:102723. doi: 10.1016/j.ijdrr.2021.102723. Epub 2021 Dec 7.
7
SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Gene.严重急性呼吸综合征冠状病毒2型德尔塔（B.1.617.2）变体：基因受体结合基序（RBM）中独特的T478K突变
Immune Netw. 2021 Oct 11;21(5):e32. doi: 10.4110/in.2021.21.e32. eCollection 2021 Oct.
8
Clinical characteristics of COVID-19 patients in Xiaogan, China: comparison between recent imported cases and earlier local cases.中国孝感新冠肺炎患者的临床特征：近期输入病例与早期本地病例的比较。
Am J Transl Res. 2021 Oct 15;13(10):11999-12005. eCollection 2021.
9
Development and Efficacy of Lateral Flow Point-of-Care Testing Devices for Rapid and Mass COVID-19 Diagnosis by the Detections of SARS-CoV-2 Antigen and Anti-SARS-CoV-2 Antibodies.通过检测SARS-CoV-2抗原和抗SARS-CoV-2抗体进行快速大规模新冠病毒诊断的侧向流动即时检测设备的开发与效能
Diagnostics (Basel). 2021 Sep 24;11(10):1760. doi: 10.3390/diagnostics11101760.
10
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.新冠疫情和疫苗更新：挑战与解决方案。
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
Zotero 插件